Pre-made Placulumab benchmark antibody ( Single Domain Variable Fragment (VL) + Fc, anti-TNFA/TNF therapeutic antibody, Anti-DIF/TNFSF2/TNLG1F Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Placulumab biosimilar, Single Domain Variable Fragment (VL + Fc), Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Placulumab is a human monoclonal antibody designed for the treatment of inflammatory diseases.
| Products Name (INN Index) | Pre-Made Placulumab biosimilar, Single Domain Variable Fragment (VL + Fc), Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody |
|---|---|
| INN Name | Placulumab |
| Target | TNF |
| Format | Single Domain Variable Fragment (VL) + Fc |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Domantis,Peptech,Arana Therapeutics,Teva Pharmaceutical Industries |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Inflammation,Psoriasis,Rheumatoid arthritis,Sciatica |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TNFA |
| Package |
